{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:48:26Z","timestamp":1792900106029,"version":"4.5.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jdcr.2023.02.010","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T02:48:58Z","timestamp":1677725338000},"page":"70-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Treatment of persistent erythema multiforme with upadacitinib: A novel therapeutic approach"],"prefix":"10.1016","volume":"34","author":[{"given":"Alana","family":"Deutsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdcr.2023.02.010_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00128071-200809020-00006","article-title":"Persistent erythema multiforme treated with thalidomide","volume":"9","author":"Chen","year":"2008","journal-title":"Am J Clin Dermatol"},{"issue":"2 Pt 2","key":"10.1016\/j.jdcr.2023.02.010_bib2","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0190-9622(95)91435-8","article-title":"Persistent erythema multiforme: report of two new cases and review of literature","volume":"33","author":"Drago","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2023.02.010_bib3","first-page":"6852189","article-title":"A case of rapidly progressing hepatocellular carcinoma after administration of JAK inhibitors to treat rheumatoid arthritis","volume":"2022","author":"Migita","year":"2022","journal-title":"Case Rep Rheumatol"},{"issue":"6","key":"10.1016\/j.jdcr.2023.02.010_bib4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/ejh.13859","article-title":"JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: final results of a phase II, open label, multicentre clinical trial (JeRiCHO)","volume":"109","author":"Gillessen","year":"2022","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.jdcr.2023.02.010_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4172\/2155-6121.1000145","article-title":"Erythema multiforme-like skin reaction induced by lenalidomide","volume":"4","author":"Kronschlager","year":"2013","journal-title":"J Allergy Ther"},{"issue":"1","key":"10.1016\/j.jdcr.2023.02.010_bib6","first-page":"40","article-title":"Thalidomide as elective treatment in persistent erythema multiforme; report of two cases","volume":"2","author":"Conejo-Mir","year":"2003","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"10.1016\/j.jdcr.2023.02.010_bib7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jamadermatol.2021.4083","article-title":"Evaluation of thalidomide treatment of patients with chronic erythema multiforme: a multicenter retrospective cohort study","volume":"157","author":"Roux","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jdcr.2023.02.010_bib8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jdcr.2016.10.009","article-title":"Idiopathic erythema multiforme: evidence of underlying Janus kinase-signal transducer and activator of transcription activation and successful treatment with tofacitinib","volume":"2","author":"Damsky","year":"2016","journal-title":"JAAD Case Rep"},{"issue":"12","key":"10.1016\/j.jdcr.2023.02.010_bib9","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamadermatol.2021.4084","article-title":"Treatment of persistent erythema multiforme with janus kinase inhibition and the role of interferon gamma and interleukin 15 in its pathogenesis","volume":"157","author":"Murphy","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262300067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235251262300067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:25:00Z","timestamp":1762475100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235251262300067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":9,"alternative-id":["S235251262300067X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.02.010","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of persistent erythema multiforme with upadacitinib: A novel therapeutic approach","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}